The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Bortezomib and Topotecan in Treating Patients With Advanced Solid Tumors
Official Title: Phase I Study of Weekly Bortezomib (VELCADE, PS-341) and Weekly Topotecan (HYCAMTIN) in Solid Tumor Patients With an Emphasis on Small Cell Lung Cancer (SCLC)
Study ID: NCT00388089
Brief Summary: RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as topotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving bortezomib together with topotecan may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of bortezomib and topotecan in treating patients with advanced solid tumors.
Detailed Description: OBJECTIVES: Primary * Evaluate the safety and feasibility of bortezomib and topotecan hydrochloride in patients with advanced solid tumors. Secondary * Determine the maximum tolerated dose (MTD) of bortezomib and topotecan hydrochloride in these patients. * Determine, preliminarily, the efficacy of this regimen in these patients. * Perform laboratory correlative studies on tumor tissue and blood samples from these patients to investigate potential predictors of response. * Obtain fresh tumor tissue for correlative studies from a subset of patients with small cell lung cancer treated at the MTD. OUTLINE: This is a dose-escalation study. Patients receive topotecan hydrochloride IV over 30 minutes followed by bortezomib IV on days 1, 8, and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients with stable or responding disease may continue to receive bortezomib alone in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of topotecan hydrochloride and bortezomib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity. Ten additional patients with small cell lung cancer are treated at the MTD. These patients undergo tumor biopsy at baseline and before the second course of therapy. Tumor tissue is collected at baseline in all patients. Blood samples are collected at baseline, at the beginning of courses 2 and 3, and after completion of study treatment. Samples are examined for topoisomerase-1 levels by western blotting; BCL-2, BCL-xL, BAX, and p27 by immunohistochemistry; hypoxia-inducible factor-1, plasminogen-activator inhibitor 1, vascular endothelial growth factor, and osteopontin by immunoenzyme techniques; and NF-kB and p27 nuclear expression by flow cytometry. After completion of study treatment, patients are followed for 30 days. PROJECTED ACCRUAL: A total of 34 patients will be accrued for this study.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
University of California Davis Cancer Center, Sacramento, California, United States
Name: Angela Davies, MD
Affiliation: University of California, Davis
Role: STUDY_CHAIR